A Phase 2 interventional study of Pimasertib and Dacarbazine in N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma, sponsored by EMD Serono. Completed at 102 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-05.
Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 284 studies in Melanoma with a site in Germany — 37 open to participants now, 71 under way, 20 of them phase 3. Melanoma · Germany.
Among the 284 studies in Melanoma with a site in Germany, this one is the 115th largest by enrollment of the 249 interventional ones that give a count, is one of 15 that started in 2012, is one of 80 in phase 2, and was the 100th registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →37 of the 284 studies in Melanoma with a site in Germany are open now. Recruiting first, the newest first:
Charite University, Berlin, Germany · Sites in Germany
Ages 18+
Bristol-Myers Squibb · Sites in Germany, United States, Belgium and 10 more countries
Ages 18+
Wuerzburg University Hospital · Sites in Germany
Ages 18+
Kupando GmbH · Sites in Germany
Ages 18+
Mitra Bio · Sites in Germany, Belgium, Spain and 1 more country
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
284 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 78 · Phase 2 124 · Phase 3 75 · Phase 4 3
First in 1995; this study’s year is marked. 15 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 194 is above the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 162 across the 249 interventional studies, 420 across the 32 observational. Of the 182 that completed or were terminated, 90 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
202 of 284 have an industry lead sponsor. The 10 most frequent:
This study is registered under EMD Serono, one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.
Merck KGaA, Darmstadt, Germany has 4 studies filed under Melanoma — fewer than ten, so there is no comparison to draw.
22 of the studies in Melanoma with a site in Germany that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05608291Phase 3Regeneron PharmaceuticalsA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | 2027-01-15 |
| NCT05987332Phase 3IDEAYA BiosciencesIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | 2027-01-15 |
| NCT05270044Phase 3Pierre Fabre MedicamentAdjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. | 2027-03-31 |
| NCT04309409Phase 3University Hospital, EssenAdjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma | 2027-09 |
| NCT06112314Phase 3Immunocore LtdIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) | 2027-10-16 |
Add all 22 to your calendar (.ics) → With an account.
Among the 284 studies in Melanoma with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, multicenter, randomized, controlled, open-label trial of pimasertib versus dacarbazine aimed to confirm the activity of pimasertib in previously untreated subjects with N-Ras mutated locally advanced or metastatic malignant cutaneous melanoma by comparing the progression-free survival (PFS) of subjects treated with either pimasertib or dacarbazine and by getting a better understanding of the efficacy, safety, pharmacogenomics (PGx) and their relationship with pimasertib exposure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pimasertib
Drug: Dacarbazine
Subjects will receive pimasertib orally as monotherapy at a dose of 60 milligram (mg) twice daily continuously. Treatment will consist of repeated 21-day cycles which will continue until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first.
Also known as: MSC1936369B, AS703026
Subjects will receive dacarbazine intravenously at dose of 1000 milligram per square meter (mg/m\^2) of body surface area every 3 weeks on Day 1 of each 21-days cycle until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first. Eligible subjects with documented tumor progression on dacarbazine will offer to switch to pimasertib treatment.
Progression Free Survival (PFS)
PFS was defined as the duration (in weeks) from randomization until the first progressive disease (PD) observation as assessed by the Investigator according to Response Evaluation Criteria for Solid Tumors (RECIST) version 1.1, or death due to any cause when death occurred within 12 weeks after the last tumor assessment (otherwise censored), whichever occurred first. PD was defined as at least a 20% increase in the sum of diameters of the target lesions, taking as reference the smallest sum since the treatment started (including baseline), or appearance of one or more new lesions, and/or unequivocal progression of existing non-target lesions.
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to cut-off date (04-Jul-2015)
Objective Response Rate (ORR)
ORR was defined as the percentage of subjects with complete response (CR) or partial response (PR) according to RECIST version 1.1 criteria. CR: defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm). PR: defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters along with absence of new lesions and disease progression in non-target lesions.
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to cut-off date (04-Jul-2015)
Disease Control Rate (DCR)
DCR was defined as the percentage of subjects with CR, PR, or stable disease (SD) for greater than (\>) 3 months assessed by investigator according to RECIST version 1.1. CR: defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than \<10 mm. PR: defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters along with absence of new lesions and disease progression in non-target lesions. SD: defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to cut-off date (04-Jul-2015)
Percentage of Subjects With Progression-free Survival (PFS) at 6 Months
PFS was defined as the duration (in weeks) from randomization until the first progressive disease (PD) observation as assessed by the Investigator according to Response Evaluation Criteria for Solid Tumors (RECIST) version 1.1, or death due to any cause when death occurred within 12 weeks after the last tumor assessment, whichever occurred first. PD was defined as at least a 20% increase in the sum of diameters of the target lesions, taking as reference the smallest sum since the treatment started (including baseline), or appearance of one or more new lesions, and/or unequivocal progression of existing non-target lesions. Percentage of Subjects with PFS at 6 Months were reported.
Time frame: 6 months
Overall Survival (OS)
OS was defined as the time (in months) from randomization to death due to any cause. Subjects without a death date were to be censored at the minimum of last known date alive, defined as the latest date available on the electronic case report form, and cut-off date.
Time frame: From date of randomization until date of death from any cause, assessed up to cut-off date (04-Jul-2015)
Percentage of Subjects With Overall Survival (OS) at 12 Months
OS was defined as the time (in months) from randomization to death due to any cause. Subjects without a death date were to be censored at the minimum of last known date alive, defined as the latest date available on the electronic case report form, and cut-off date. Percentage of Subjects with OS at 12 months were reported.
Time frame: 12 months
Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT)
QoL assessed using Function Assessment Cancer Therapy-melanoma (FACT-M) assessment tool. This includes 27-item FACT-General (FACT-G) questionnaire which consists of 24 questions;7 relating to physical well-being (PWB),7 relating to social/family well-being (SWB),6 relating to emotional well-being (EWB) and 7 relating to functional well-being (FWB). Also, it includes melanoma-specific subscale consists of 16 questions for Melanoma Subscale (MS) and 8 questions for Melanoma Surgery Scale (MSS).Each of these questions could have a response of Not at all, a little bit, somewhat, quite a bit and very much. The responses were given a value between 0 and 4 with 4 being best response. The FACT-M Total Score (FACT-M TS) ranges from 0 to 172 and is derived as follows: FACT-M TS= PWB Score + SWB Score + EWB Score + FWB Score + MS Score. Higher scores represent a better quality of life.
Time frame: Baseline, Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 30, 31, 32, 33, 35, 36, 37 and EOT (up to cut-off date [04-Jul-2015])
Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT)
QoL assessed using FACT-M assessment tool. This includes 27-item FACT-G questionnaire which consists of 24 questions; 7 relating to PWB, 7 relating to SWB, 6 relating to EWB and 7 relating to FWB. Also, it includes melanoma-specific subscale consists of 16 questions for MS and 8 questions for the MSS. Each of these questions could have a response of Not at all, a little bit, somewhat, quite a bit and very much. The responses were given a value between 0 and 4 with 4 being best response. The FACT-M Trial Outcome Index (FACT-M TOI) ranges from 0 to a high of 120 and is derived as: FACT-M TOI = PWB Score + FWB Score +MS Score. Higher scores represent a better quality of life.
Time frame: Baseline, Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 30, 31, 32, 33, 35, 36, 37 and EOT (up to cut-off date [04-Jul-2015])
Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation or TEAEs Leading to Death
AE was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug and up to 33 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. TEAEs include both Serious TEAEs and non-serious TEAEs. TEAEs were to be reported separately for dacarbazine, pimasertib and pimasertib (crossover) reporting arms.
Time frame: Baseline up to cut-off date (04-Jul-2015)
Number of Subjects With Adverse Events (AEs) of Special Interest
Adverse events of special interest included ocular retinal vein occlusion, serious retinal detachment or similar retinal abnormality characterized by accumulation of serous fluid in the retina, creatine phosphokinase (CPK) elevation and isoenzyme TEAE of Special Interest (Grade \>=2) and acute renal failure (Grade \>=2). Subjects were presented under 3 reporting groups: Dacarbazine group: for subjects who received at least 1 dose of dacarbazine; Pimasertib group: for subjects who received at least 1 dose of pimasertib; Pimasertib (Crossover) group: for subjects who were initially randomized and received dacarbazine, but crossed over to pimasertib treatment on progression of their disease.
Time frame: Baseline up to cut-off date (04-Jul-2015)
Number of Subjects With Clinically Significant Change From Baseline in Laboratory Parameter, Vital Signs, Electrocardiogram (ECG) and Ophthalmologic Findings
Subjects were presented under 3 reporting groups: Dacarbazine group: for subjects who received at least 1 dose of dacarbazine; Pimasertib group: for subjects who received at least 1 dose of pimasertib; Pimasertib (Crossover) group: for subjects who were initially randomized and received dacarbazine, but crossed over to pimasertib treatment on progression of their disease.
Time frame: Baseline up to cut-off date (04-Jul-2015)
First/last subject (informed consent): 05 December 2012/04 June 2014. Cut-off date: 04 July 2015. Last subject last visit: 24 October 2016.
| Milestone | Dacarbazine | Pimasertib | Pimasertib (Crossover) |
|---|---|---|---|
| Started | 64 | 130 | 0 |
| Treated | 61 | 130 | 0 |
| Completed | 62 | 125 | 0 |
| Not completed | 2 | 5 | 0 |
| Withdrew: On-study | 2 | 5 | 0 |
| Milestone | Dacarbazine | Pimasertib | Pimasertib (Crossover) |
|---|---|---|---|
| Started | 0 | 0 | 41 |
| Treated | 0 | 0 | 41 |
| Completed | 0 | 0 | 40 |
| Not completed | 0 | 0 | 1 |
| Withdrew: On-study | 0 | 0 | 1 |
PFS was defined as the duration (in weeks) from randomization until the first progressive disease (PD) observation as assessed by the Investigator according to Response Evaluation Criteria for Solid Tumors (RECIST) version 1.1, or death due to any cause when death occurred within 12 weeks after the last tumor assessment (otherwise censored), whichever occurred first. PD was defined as at least a 20% increase in the sum of diameters of the target lesions, taking as reference the smallest sum since the treatment started (including baseline), or appearance of one or more new lesions, and/or unequivocal progression of existing non-target lesions.
| weeks | Dacarbazine | Pimasertib |
|---|---|---|
| Progression Free Survival (PFS) | 6.86 (6.00 to 12.14) | 13.00 (12.29 to 17.71) |
ORR was defined as the percentage of subjects with complete response (CR) or partial response (PR) according to RECIST version 1.1 criteria. CR: defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm). PR: defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters along with absence of new lesions and disease progression in non-target lesions.
| percentage of subjects | Dacarbazine | Pimasertib |
|---|---|---|
| Objective Response Rate (ORR) | 14.1 (6.6 to 25.0) | 26.9 (19.5 to 35.4) |
DCR was defined as the percentage of subjects with CR, PR, or stable disease (SD) for greater than (\>) 3 months assessed by investigator according to RECIST version 1.1. CR: defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than \<10 mm. PR: defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters along with absence of new lesions and disease progression in non-target lesions. SD: defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
| percentage of subjects | Dacarbazine | Pimasertib |
|---|---|---|
| Disease Control Rate (DCR) | 15.6 (7.8 to 26.9) | 33.1 (25.1 to 41.9) |
PFS was defined as the duration (in weeks) from randomization until the first progressive disease (PD) observation as assessed by the Investigator according to Response Evaluation Criteria for Solid Tumors (RECIST) version 1.1, or death due to any cause when death occurred within 12 weeks after the last tumor assessment, whichever occurred first. PD was defined as at least a 20% increase in the sum of diameters of the target lesions, taking as reference the smallest sum since the treatment started (including baseline), or appearance of one or more new lesions, and/or unequivocal progression of existing non-target lesions. Percentage of Subjects with PFS at 6 Months were reported.
| percentage of subjects | Dacarbazine | Pimasertib |
|---|---|---|
| Percentage of Subjects With Progression-free Survival (PFS) at 6 Months | 9.4 (3.6 to 18.6) | 17.3 (10.2 to 26.0) |
OS was defined as the time (in months) from randomization to death due to any cause. Subjects without a death date were to be censored at the minimum of last known date alive, defined as the latest date available on the electronic case report form, and cut-off date.
| months | Dacarbazine | Pimasertib |
|---|---|---|
| Overall Survival (OS) | 10.61 (7.26 to 16.49) | 8.87 (7.46 to 15.51) |
OS was defined as the time (in months) from randomization to death due to any cause. Subjects without a death date were to be censored at the minimum of last known date alive, defined as the latest date available on the electronic case report form, and cut-off date. Percentage of Subjects with OS at 12 months were reported.
| percentage of subjects | Dacarbazine | Pimasertib |
|---|---|---|
| Percentage of Subjects With Overall Survival (OS) at 12 Months | 44.5 (31.6 to 56.6) | 43.3 (34.5 to 51.8) |
QoL assessed using Function Assessment Cancer Therapy-melanoma (FACT-M) assessment tool. This includes 27-item FACT-General (FACT-G) questionnaire which consists of 24 questions;7 relating to physical well-being (PWB),7 relating to social/family well-being (SWB),6 relating to emotional well-being (EWB) and 7 relating to functional well-being (FWB). Also, it includes melanoma-specific subscale consists of 16 questions for Melanoma Subscale (MS) and 8 questions for Melanoma Surgery Scale (MSS).Each of these questions could have a response of Not at all, a little bit, somewhat, quite a bit and very much. The responses were given a value between 0 and 4 with 4 being best response. The FACT-M Total Score (FACT-M TS) ranges from 0 to 172 and is derived as follows: FACT-M TS= PWB Score + SWB Score + EWB Score + FWB Score + MS Score. Higher scores represent a better quality of life.
| units on a scale | Dacarbazine | Pimasertib |
|---|---|---|
| Baseline | 126.20 ± 23.828 | 132.24 ± 22.179 |
| Change at Day 1 Cycle 2 | -3.05 ± 14.815 | -3.06 ± 18.492 |
| Change at Day 1 Cycle 3 | 0.60 ± 19.965 | -6.77 ± 21.716 |
| Change at Day 1 Cycle 4 | 4.11 ± 14.746 | -6.54 ± 19.919 |
| Change at Day 1 Cycle 5 | 0.62 ± 11.810 | -2.81 ± 17.202 |
| Change at Day 1 Cycle 6 | -3.71 ± 15.674 | -8.45 ± 20.939 |
| Change at Day 1 Cycle 7 | -1.10 ± 13.318 | -8.84 ± 19.128 |
| Change at Day 1 Cycle 8 | 1.28 ± 12.928 | -14.67 ± 18.508 |
| Change at Day 1 Cycle 9 | 2.21 ± 16.224 | -13.67 ± 21.388 |
| Change at Day 1 Cycle 10 | 4.40 ± 14.818 | -13.26 ± 20.716 |
| Change at Day 1 Cycle 11 | 1.02 ± 19.161 | -14.10 ± 21.157 |
| Change at Day 1 Cycle 12 | 1.56 ± 19.932 | -10.52 ± 18.895 |
| Change at Day 1 Cycle 13 | 5.51 ± 20.191 | -13.38 ± 23.690 |
| Change at Day 1 Cycle 14 | 11.50 ± 21.920 | -18.24 ± 22.998 |
| Change at Day 1 Cycle 15 | 9.60 ± 15.345 | -11.33 ± 19.787 |
| Change at Day 1 Cycle 16 | 10.56 ± 14.935 | -11.18 ± 23.680 |
| Change at Day 1 Cycle 17 | 3.00 ± 5.657 | -9.18 ± 24.166 |
| Change at Day 1 Cycle 18 | 27.00 ± NA | -3.92 ± 9.640 |
| Change at Day 1 Cycle 19 | 16.50 ± 14.849 | -1.15 ± 8.147 |
| Change at Day 1 Cycle 20 | 16.00 ± 15.556 | 1.17 ± 5.947 |
| Change at Day 1 Cycle 21 | 17.00 ± 14.142 | 4.17 ± 8.918 |
| Change at Day 1 Cycle 22 | 18.00 ± 12.728 | 1.32 ± 11.163 |
| Change at Day 1 Cycle 23 | 27.00 ± NA | -13.69 ± 15.354 |
| Change at Day 1 Cycle 24 | 13.50 ± 19.092 | -3.83 ± NA |
| Change at Day 1 Cycle 25 | 14.50 ± 17.678 | -3.83 ± NA |
| Change at Day 1 Cycle 26 | 27.00 ± NA | -2.83 ± NA |
| Change at Day 1 Cycle 27 | 27.00 ± NA | — |
| Change at Day 1 Cycle 28 | 27.00 ± NA | -0.83 ± NA |
| Change at Day 1 Cycle 30 | — | -1.83 ± NA |
| Change at Day 1 Cycle 31 | — | -7.83 ± NA |
| Change at Day 1 Cycle 32 | — | -7.83 ± NA |
| Change at Day 1 Cycle 33 | — | -8.83 ± NA |
| Change at Day 1 Cycle 35 | — | -1.83 ± NA |
| Change at Day 1 Cycle 36 | — | -3.83 ± NA |
| Change at Day 1 Cycle 37 | — | -4.83 ± NA |
| Change at EOT | -7.91 ± 23.119 | -9.98 ± 20.560 |
QoL assessed using FACT-M assessment tool. This includes 27-item FACT-G questionnaire which consists of 24 questions; 7 relating to PWB, 7 relating to SWB, 6 relating to EWB and 7 relating to FWB. Also, it includes melanoma-specific subscale consists of 16 questions for MS and 8 questions for the MSS. Each of these questions could have a response of Not at all, a little bit, somewhat, quite a bit and very much. The responses were given a value between 0 and 4 with 4 being best response. The FACT-M Trial Outcome Index (FACT-M TOI) ranges from 0 to a high of 120 and is derived as: FACT-M TOI = PWB Score + FWB Score +MS Score. Higher scores represent a better quality of life.
| units on a scale | Dacarbazine | Pimasertib |
|---|---|---|
| Baseline | 90.35 ± 19.348 | 94.07 ± 17.534 |
| Change at Day 1 Cycle 2 | -3.33 ± 12.015 | -4.40 ± 14.286 |
| Change at Day 1 Cycle 3 | -0.69 ± 15.974 | -7.99 ± 17.089 |
| Change at Day 1 Cycle 4 | 1.54 ± 10.304 | -7.97 ± 16.741 |
| Change at Day 1 Cycle 5 | -0.86 ± 5.405 | -4.37 ± 14.084 |
| Change at Day 1 Cycle 6 | -3.29 ± 7.752 | -9.15 ± 18.813 |
| Change at Day 1 Cycle 7 | -2.07 ± 6.859 | -8.99 ± 14.783 |
| Change at Day 1 Cycle 8 | 0.83 ± 5.161 | -15.09 ± 14.458 |
| Change at Day 1 Cycle 9 | -1.93 ± 6.300 | -13.79 ± 17.198 |
| Change at Day 1 Cycle 10 | -1.10 ± 5.654 | -12.37 ± 17.058 |
| Change at Day 1 Cycle 11 | -2.90 ± 7.722 | -13.95 ± 17.006 |
| Change at Day 1 Cycle 12 | -2.40 ± 7.408 | -11.95 ± 17.311 |
| Change at Day 1 Cycle 13 | 0.80 ± 7.697 | -13.57 ± 21.699 |
| Change at Day 1 Cycle 14 | 0.00 ± 4.243 | -18.55 ± 19.880 |
| Change at Day 1 Cycle 15 | 1.60 ± 4.084 | -13.59 ± 15.747 |
| Change at Day 1 Cycle 16 | 0.61 ± 3.994 | -13.15 ± 19.130 |
| Change at Day 1 Cycle 17 | 2.50 ± 0.707 | -10.66 ± 20.007 |
| Change at Day 1 Cycle 18 | 3.00 ± NA | -5.72 ± 4.614 |
| Change at Day 1 Cycle 19 | 2.50 ± 0.707 | -4.94 ± 5.238 |
| Change at Day 1 Cycle 20 | 4.00 ± 1.414 | -2.33 ± 1.155 |
| Change at Day 1 Cycle 21 | 3.50 ± 0.707 | 0.00 ± 2.000 |
| Change at Day 1 Cycle 22 | 4.00 ± 1.414 | -1.40 ± 3.831 |
| Change at Day 1 Cycle 23 | 3.00 ± NA | -13.36 ± 16.061 |
| Change at Day 1 Cycle 24 | 2.50 ± 0.707 | -2.00 ± NA |
| Change at Day 1 Cycle 25 | 3.50 ± 0.707 | -1.00 ± NA |
| Change at Day 1 Cycle 26 | 3.00 ± NA | 0.00 ± NA |
| Change at Day 1 Cycle 27 | 3.00 ± NA | — |
| Change at Day 1 Cycle 28 | 3.00 ± NA | 1.00 ± NA |
| Change at Day 1 Cycle 30 | — | 1.00 ± NA |
| Change at Day 1 Cycle 31 | — | -3.00 ± NA |
| Change at Day 1 Cycle 32 | — | -4.00 ± NA |
| Change at Day 1 Cycle 33 | — | -3.00 ± NA |
| Change at Day 1 Cycle 35 | — | 0.00 ± NA |
| Change at Day 1 Cycle 36 | — | 0.00 ± NA |
| Change at Day 1 Cycle 37 | — | -3.00 ± NA |
| Change at EOT | -8.18 ± 16.410 | -10.42 ± 16.256 |
AE was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug and up to 33 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. TEAEs include both Serious TEAEs and non-serious TEAEs. TEAEs were to be reported separately for dacarbazine, pimasertib and pimasertib (crossover) reporting arms.
| subjects | Dacarbazine | Pimasertib | Pimasertib (Crossover) |
|---|---|---|---|
| TEAEs | 60 | 130 | 41 |
| Serious TEAEs | 12 | 74 | 26 |
| TEAEs Leading to Discontinuation | 3 | 61 | 16 |
| TEAEs Leading To Death | 4 | 6 | 6 |
Adverse events of special interest included ocular retinal vein occlusion, serious retinal detachment or similar retinal abnormality characterized by accumulation of serous fluid in the retina, creatine phosphokinase (CPK) elevation and isoenzyme TEAE of Special Interest (Grade \>=2) and acute renal failure (Grade \>=2). Subjects were presented under 3 reporting groups: Dacarbazine group: for subjects who received at least 1 dose of dacarbazine; Pimasertib group: for subjects who received at least 1 dose of pimasertib; Pimasertib (Crossover) group: for subjects who were initially randomized and received dacarbazine, but crossed over to pimasertib treatment on progression of their disease.
| subjects | Dacarbazine | Pimasertib | Pimasertib (Crossover) |
|---|---|---|---|
| Retinal vein occlusion | 0 | 5 | 2 |
| Serious retinal detachment | 0 | 76 | 21 |
| CPK/Isoenzyme TEAE of Special Interest (>=Grade 2) | 0 | 74 | 24 |
| Acute renal failure (Grade >= 2) | 1 | 9 | 2 |
Subjects were presented under 3 reporting groups: Dacarbazine group: for subjects who received at least 1 dose of dacarbazine; Pimasertib group: for subjects who received at least 1 dose of pimasertib; Pimasertib (Crossover) group: for subjects who were initially randomized and received dacarbazine, but crossed over to pimasertib treatment on progression of their disease.
| subjects | Dacarbazine | Pimasertib | Pimasertib (Crossover) |
|---|---|---|---|
| Laboratory Parameter | 0 | 0 | 0 |
| Vital Signs | 0 | 0 | 0 |
| ECG | 0 | 0 | 0 |
| Ophthalmologic Findings | 0 | 0 | 0 |
Collected over Baseline up to cut-off date (04-Jul-2015). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dacarbazine | — | 12/61 (19.7%) | 59/61 (96.7%) |
| Pimasertib | — | 74/130 (56.9%) | 130/130 (100%) |
| Pimasertib (Crossover) | — | 26/41 (63.4%) | 41/41 (100%) |
| Event | Dacarbazine | Pimasertib | Pimasertib (Crossover) |
|---|---|---|---|
| Blood creatine phosphokinase increasedInvestigations | 0/61 | 26/130 | 8/41 |
| General physical health deteriorationGeneral disorders | 1/61 | 2/130 | 4/41 |
| ErysipelasInfections and infestations | 0/61 | 7/130 | 1/41 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/61 | 0/130 | 0/41 |
| AnaemiaBlood and lymphatic system disorders | 1/61 | 0/130 | 2/41 |
| Small intestinal obstructionGastrointestinal disorders | 0/61 | 0/130 | 2/41 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/61 | 3/130 | 2/41 |
| DiarrhoeaGastrointestinal disorders | 1/61 | 6/130 | 1/41 |
| Ejection fraction decreasedInvestigations | 0/61 | 5/130 | 1/41 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/61 | 5/130 | 0/41 |
| Event | Dacarbazine | Pimasertib | Pimasertib (Crossover) |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 10/61 | 106/130 | 31/41 |
| Blood creatine phosphokinase increasedInvestigations | 3/61 | 86/130 | 28/41 |
| Oedema peripheralGeneral disorders | 6/61 | 59/130 | 18/41 |
| RashSkin and subcutaneous tissue disorders | 5/61 | 46/130 | 18/41 |
| Retinal detachmentEye disorders | 0/61 | 56/130 | 15/41 |
| NauseaGastrointestinal disorders | 25/61 | 47/130 | 17/41 |
| VomitingGastrointestinal disorders | 14/61 | 30/130 | 16/41 |
| FatigueGeneral disorders | 23/61 | 39/130 | 11/41 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 0/61 | 47/130 | 9/41 |
| ConstipationGastrointestinal disorders | 21/61 | 24/130 | 7/41 |
Intent-to-treat (ITT) analysis set included all subjects who were randomized to trial treatment.
| Age, Categorical(Participants) | Dacarbazine | Pimasertib | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 36 | 65 | 101 |
| >=65 years | 28 | 65 | 93 |
| Sex: Female, Male(Participants) | Dacarbazine | Pimasertib | Total |
|---|---|---|---|
| Female | 28 | 62 | 90 |
| Male | 36 | 68 | 104 |
Showing the first 100 of 102 sites across 14 countries. Choose a country and city above to see the rest.
Ran from Dec 2012 to primary completion in Jul 2015, 30 months.
Results were first posted in Jan 2018, 2 years 6 months after primary completion.
Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 30 months is below that.
Counting every sponsor, half of 384 studies reached it within 53 months; a quarter within 32 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pimasertib